A Study of Carbamazepine (CBZ) and MK-8527 in Healthy Adult Participants (MK-8527-012)

Completed · Phase 1

Conditions studied: Healthy

In brief

The goal of this study is to learn what happens to MK-8527 in a healthy person's body over time when MK-8527 is given alone and with the medication CBZ.

Key facts

Study ID

NCT06893081

Run by

Merck Sharp & Dohme LLC

People needed

16

Starts

2025-04-28

Expected to finish

2025-07-17

Last updated by the study team

2025-07-29

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Inclusion criteria include, but are not limited to:
• Is a healthy, adult, male or female of non-childbearing potential only, 18-55 years of age, inclusive
• Is a continuous non-smoker who has not used nicotine- and tobacco-containing products for at least 3 months prior

You may not qualify if…

• Exclusion criteria include, but are not limited to:
• Has a history or presence of:
• Seizures (except for febrile seizure), or is at an increased risk for seizures
• Family history of severe dermatologic reactions including toxic epidermal necrolysis and Stevens-Johnson syndrome
• Clinically meaningful hematologic diseases, bone marrow disorders, or hematologic adverse reactions to other medications
• Depression, unusual changes in mood or behavior or suicidal thoughts or behavior
• Hypersensitivity reaction to anticonvulsant therapy (including phenytoin, primidone, and phenobarbital)
• Clinically significant eye disease
• Cardiac conduction disturbance, including second-and third-degree atrioventricular heart block
• Shown to carry or be positive for HLA-A*11:01, HLA-A*31:01, HLA-B*15:02, HLA-B*15:08, HLA-B*15:11, HLA-B*15:21, HLA-B*15:30, or HLA-B*15:31 alleles.

Where it is running

• Celerion ( Site 0001) — Tempe, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.